{"id":33231,"date":"2024-11-01T16:06:18","date_gmt":"2024-11-01T16:06:18","guid":{"rendered":"https:\/\/bnssghealthiertogether.org.uk\/?page_id=33231"},"modified":"2025-01-16T22:24:48","modified_gmt":"2025-01-16T22:24:48","slug":"proactive-hepatitis-c-reinfection-optimising-surveillance-for-detection-and-prevention","status":"publish","type":"page","link":"https:\/\/bnssghealthiertogether.org.uk\/tr\/integrated-care-board\/research-and-evidence\/our-research-portfolio\/nihr-funded-projects\/proactive-hepatitis-c-reinfection-optimising-surveillance-for-detection-and-prevention\/","title":{"rendered":"PROAKT\u0130F: Hepatit C Yeniden Enfeksiyonu: Tespit ve \u00d6nleme i\u00e7in G\u00f6zetimin Optimize Edilmesi"},"content":{"rendered":"<div class=\"assembler_default-group assembler_module_group assembler_default-group_1 assembler_module_group_1\"><div class=\"assembler_module_area assembler_module_area_1\"><div class=\"assembler_text-module assembler_module assembler_text-module_1 assembler_module_1  transparent\"><a tabindex=\"-1\" title=\"Mod\u00fcl-1 ba\u015fl\u0131kl\u0131 b\u00f6l\u00fcm\" id=\"module-1\" href=\"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/pages\/33231\/#module-1\" class=\"anchor\"><span class=\"hidden\">Mod\u00fcl-1 ba\u015fl\u0131kl\u0131 b\u00f6l\u00fcm<\/span><\/a><!-- Template found for text-module - Template: template-text - Matched: _only --><section class=\"w-full mx-auto max-w-content pt-12 sm:pt-24 pb-12 sm:pb-24\">\r\n  <div class=\"entry-content w-full !px-0 max-w-small\">\r\n        <h1>PROAKT\u0130F: Hepatit C Yeniden Enfeksiyonu: Tespit ve \u00d6nleme i\u00e7in G\u00f6zetimin Optimize Edilmesi<\/h1>\n<h2>Finansman<\/h2>\n<p>Ulusal Sa\u011fl\u0131k ve Bak\u0131m Ara\u015ft\u0131rma Enstit\u00fcs\u00fc (NIHR), Program Geli\u015ftirme Hibesi (PDG) Referans No: NIHR207646<\/p>\n<h2>Ara\u015ft\u0131rma sorusu nedir?<\/h2>\n<p>Hepatit C i\u00e7in takip testlerinin \u00f6n\u00fcndeki engeller nelerdir ve uyu\u015fturucu enjekte edenler yeniden enfeksiyon riskini nas\u0131l azaltabilirler?<\/p>\n<h2>Sorun nedir?<\/h2>\n<p>Hepatit C vir\u00fcs\u00fc karaci\u011feri etkiler ve tedavi edilmedi\u011fi takdirde uzun s\u00fcreli Hepatit C enfeksiyonu karaci\u011fer hasar\u0131na, kansere ve erken \u00f6l\u00fcme yol a\u00e7abilir. Bununla birlikte, tedaviler Hepatit C enfeksiyonunu h\u0131zl\u0131 ve etkili bir \u015fekilde iyile\u015ftirebilir. Bu nedenle D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc, 2030 y\u0131l\u0131na kadar Hepatit C ile m\u00fccadele etmeyi hedeflemi\u015ftir.<\/p>\n<p>\u0130ngiltere&#039;de Hepatit C enfeksiyonu ve yeniden enfeksiyonu ya\u015fayan ki\u015filerin b\u00fcy\u00fck \u00e7o\u011funlu\u011funu uyu\u015fturucu enjekte edenler olu\u015fturmaktad\u0131r.<\/p>\n<p>2017 y\u0131l\u0131nda yap\u0131lan \u00f6nceki ara\u015ft\u0131rmalarda, uyu\u015fturucu enjekte eden ki\u015filerde Hepatit C testi ve tedavisi h\u0131zla yayg\u0131nla\u015ft\u0131r\u0131ld\u0131 ve\u00a0<a href=\"https:\/\/bnssg.icb.nhs.uk\/about-us\/research-and-evidence\/our-research-portfolio\/nihr-funded-projects\/epitope-evaluating-the-population-impact-of-hepatitis-c-direct-acting-antiviral-treatment-as-prevention-for-people-who-inject-drugs\/\" rel=\"noopener\">ara\u015ft\u0131rmam\u0131z<\/a>\u00a0Bu y\u00f6ntemin Hepatit C enfeksiyonlar\u0131n\u0131 azaltmada son derece etkili oldu\u011fu g\u00f6sterilmi\u015ftir.<\/p>\n<p>Ancak, Hepatit C enfeksiyonlar\u0131n\u0131 d\u00fc\u015f\u00fck seviyede tutmak i\u00e7in, gelecekteki yeniden enfeksiyonlar\u0131 \u00f6nlememiz ve yeniden enfeksiyonu h\u0131zl\u0131 bir \u015fekilde tespit edip tedavi etmemiz gerekiyor. K\u0131lavuzlar, Hepatit C tedavisi g\u00f6rm\u00fc\u015f ki\u015filerin yeniden enfeksiyon olup olmad\u0131\u011f\u0131n\u0131 kontrol etmek i\u00e7in y\u0131lda bir kez test edilmesini \u00f6nermektedir. Bununla birlikte, ara\u015ft\u0131rmam\u0131z bu takibin nadiren yap\u0131ld\u0131\u011f\u0131n\u0131 g\u00f6stermektedir.<\/p>\n<h2>Ara\u015ft\u0131rman\u0131n amac\u0131 nedir?<\/h2>\n<p>Bu \u00e7al\u0131\u015fman\u0131n \u00fc\u00e7 amac\u0131 vard\u0131r:<\/p>\n<ol>\n<li>Takip testlerinin yap\u0131lmas\u0131n\u0131 kolayla\u015ft\u0131ran ve engelleyen fakt\u00f6rleri belirlemek.<\/li>\n<li>\u0130nsanlar\u0131n test yapt\u0131r\u0131rken hangi bilgilerin topland\u0131\u011f\u0131n\u0131 \u00f6\u011frenmek, gelecekte yeniden enfeksiyon riskini azaltmam\u0131za yard\u0131mc\u0131 olabilecek fakt\u00f6rleri anlamam\u0131za katk\u0131 sa\u011flayabilir.<\/li>\n<li>Gelecekteki uygulamalar i\u00e7in birlikte k\u0131lavuz olu\u015fturun.<\/li>\n<\/ol>\n<h2>Bu nas\u0131l ba\u015far\u0131lacak?<\/h2>\n<p>Bu ara\u015ft\u0131rman\u0131n ama\u00e7lar\u0131na \u00fc\u00e7 a\u015famada ula\u015f\u0131lacakt\u0131r:<\/p>\n<ol>\n<li>Bug\u00fcne kadarki kan\u0131tlar\u0131n kapsaml\u0131 incelemesi<\/li>\n<li>Uyu\u015fturucu enjekte eden ki\u015filerle ve y\u0131ll\u0131k testleri yapan personelle yap\u0131lan nitel g\u00f6r\u00fc\u015fmeler.<\/li>\n<li>1. ve 2. b\u00f6l\u00fcmlerden elde edilen bulgular, d\u00f6rt ortak \u00fcretim oturumuna katk\u0131da bulunacakt\u0131r. Bunlardan ikisi Hepatit C uzmanlar\u0131, Hepatit C testi yapan personel ve politika yap\u0131c\u0131larla, di\u011fer ikisi ise bu durumu bizzat ya\u015fam\u0131\u015f ki\u015filerle ger\u00e7ekle\u015ftirilecektir. \u015eunlar\u0131 ele alaca\u011f\u0131z:<\/li>\n<\/ol>\n<ul>\n<li>Belirlenen engellerin nas\u0131l a\u015f\u0131labilece\u011fi,<\/li>\n<li>Y\u0131ll\u0131k s\u0131nav teklifinin nas\u0131l daha iyi hale getirilebilece\u011fi<\/li>\n<li>ve Hepatit C yeniden enfeksiyon oranlar\u0131n\u0131n ulusal d\u00fczeyde izlenmesini desteklemek i\u00e7in gereken bilgiler<\/li>\n<\/ul>\n<h2>Ara\u015ft\u0131rmay\u0131 kim y\u00f6netiyor?<\/h2>\n<p>Dr. Hannah Family, Bristol \u00dcniversitesi<\/p>\n<h2>Daha fazla bilgi:<\/h2>\n<p>CI E-postas\u0131:\u00a0<a href=\"mailto:hannah.family@bristol.ac.uk\">hannah.family@bristol.ac.uk<\/a>\u00a0veya\u00a0<a href=\"mailto:Hannah.family@nhs.net\">Hannah.family@nhs.net<\/a><\/p>\n<p>Daha fazla bilgi almak veya bu projeye kat\u0131lmak i\u00e7in l\u00fctfen e-posta g\u00f6nderin. <a href=\"mailto:bnssg.research@nhs.net\">bnssg.research@nhs.net<\/a>.<\/p>\n<p>Burada ifade edilen g\u00f6r\u00fc\u015fler yazar(lar)a aittir ve NIHR veya Sa\u011fl\u0131k ve Sosyal Bak\u0131m Bakanl\u0131\u011f\u0131&#039;n\u0131n g\u00f6r\u00fc\u015flerini yans\u0131tmayabilir.<\/p>\n  <\/div>\r\n  <\/section><\/div><!-- .assembler_text-module.assembler_module.assembler_text-module_1.assembler_module_1..transparent --><\/div><!-- .assembler_module_area.assembler_module_area_1 --><\/div><!-- .assembler_default-group.assembler_module_group.assembler_default-group_1.assembler_module_group_1  -->","protected":false},"excerpt":{"rendered":"<p>Section titled module-1 PROACTIVE: HePatitis C Reinfection: Optimising surveillAnCe for detection and preVEntion Funding National Institute for Health and Care Research (NIHR) , Programme Development Grant (PDG) Ref. NIHR207646 What is the Research Question? What are the barriers to follow up testing for Hepatitis C, \u00a0and how can those who inject drugs reduce their risk [&hellip;]<\/p>\n","protected":false},"author":28,"featured_media":0,"parent":32881,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"tags":[],"class_list":["post-33231","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/pages\/33231","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/comments?post=33231"}],"version-history":[{"count":3,"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/pages\/33231\/revisions"}],"predecessor-version":[{"id":36171,"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/pages\/33231\/revisions\/36171"}],"up":[{"embeddable":true,"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/pages\/32881"}],"wp:attachment":[{"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/media?parent=33231"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/tags?post=33231"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}